Onkologiske legemidler: Utviklingen fra konvensjonelle cytostatika til nib-er, mab-er og andre nyvinninger
Sammanfattning
New medicines for the treatment of cancer diseases have been the subject of many media reviews lately. Many new drugs have been developed due to a deeper understanding of the molecular biology behind cancerous diseases. Many of these new active substances are protein kinase inhibitors (nibs) or monoclonal antibodies (mabs), two drug classes with different characteristics. The new drugs have a more specific biological mechanism, which allow more targeted and personalized therapy. These new drugs are widely used in the clinic, often in combination with older drugs. Despite the recent promising developments, there is for many indications a great need for new therapies. Several new oncologic drugs originating from Norwegian research communities are in clinical trials or are already approved.